Log in to search using one of your social media accounts:

 

FDA OKs Durvalumab (Imfinzi) for Reducing Risk for NSCLC Progression FDA OKs Durvalumab (Imfinzi) for Reducing Risk for NSCLC Progression
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs Durvalumab for Reducing Risk for NSCLC Progression FDA OKs Durvalumab for Reducing Risk for NSCLC Progression
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed. (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Overlooked Biomarker May Predict Cancer Immunotherapy Response Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 15, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

In mice, a single vaccine prompts the immune system to fight breast, lung and skin cancers
In the field of regenerative medicine, induced pluripotent stem cells have a lot of neat tricks up their sleeves. One of them may be teaching the immune system how to beat back cancer.In research that could open a new frontier in the young field of cancer immunotherapy, Stanford University scientists... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - February 15, 2018 Category: Science Authors: Melissa Healy Source Type: news

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. (Source: Reuters: Health)
Source: Reuters: Health - February 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

NCCN teams up with ASCO to provide guidelines for use of new cancer-fighting drugs
The Montgomery County-based-based National Comprehensive Cancer Network and the American Society of Clinical Oncology have published new guidelines to help clinicians manage side effects related to immune checkpoint inhibitors used in immunotherapy treatments. Immunotherapy, which is revolutionizing the way some cancers are being treated, aims at improving the way a patient's own immune system identifies and attacks invading tumors. Immune checkpoint inhibitors are drugs – often made of antibodies… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2018 Category: Pharmaceuticals Authors: John George Source Type: news

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Many human cancers are resistant to immunotherapy, for reasons that are poorly understood. We used a genome-scale CRISPR-Cas9 screen to identify mechanisms of tumor cell resistance to killing by cytotoxic T cells, the central effectors of antitumor immunity. Inactivation of>100 genes—including Pbrm1, Arid2, and Brd7, which encode components of the PBAF form of the SWI/SNF chromatin remodeling complex—sensitized mouse B16F10 melanoma cells to killing by T cells. Loss of PBAF function increased tumor cell sensitivity to interferon-, resulting in enhanced secretion of chemokines that recruit effector T cells. T...
Source: ScienceNOW - February 15, 2018 Category: Science Authors: Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., Wucherpfennig, K. W. Tags: Medicine, Diseases r-articles Source Type: news

For one early adopter, CAR T therapy means 18 months cancer-free and counting
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Source: UCLA Newsroom: Health Sciences - February 14, 2018 Category: Universities & Medical Training Source Type: news

Bristol-Myers signs record biotech partnership deal
Drugmaker to pay Nektar $1.85bn upfront in hope of boosting cancer immunotherapies (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 14, 2018 Category: Pharmaceuticals Source Type: news

Nektar lands record $3.6B deal with Bristol-Myers Squibb for cancer immunotherapy
Bristol-Myers Squibb (NYSE:BMY) could fork over as much as $3.63 billion for the rights to Nektar Therapeutics‘ (NSDQ:NKTR) cancer immunotherapy drug, according to a deal announced today by the two companies. Nektar’s NKTR-214, which is still in development, is designed to boost the number of cancer-killing T-cells around the tumor’s micro-environment. Bristol-Myers Squibb plans to pair the investigational therapy with its own cancer drug, Opdivo, across more than 20 indications in nine tumor types. Get the full story at our sister site, Drug Delivery Business News. The post Nektar lands record ...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Oncology Pharmaceuticals Research & Development Wall Street Beat Bristol-Myers Squibb Co. nektartherapeutics Source Type: news

' Unprecedented' 73% Response Rate With Combo in Untreated RCC'Unprecedented' 73% Response Rate With Combo in Untreated RCC
The combination of an immunotherapy and a VEGF inhibitor for the initial treatment of advanced renal cell carcinoma yielded groundbreaking results. And it is not intolerably toxic.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news

IRB Barcelona paves the way to the use of immunotherapy to treat aggressive colon tumors
(Institute for Research in Biomedicine (IRB Barcelona)) The researchers developed a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2018 Category: Cancer & Oncology Source Type: news

Response of High-Grade Gliomas to Checkpoint Inhibitors Response of High-Grade Gliomas to Checkpoint Inhibitors
How should MRI findings be used to assess response of high-grade gliomas to immunotherapy?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Local Immunotherapy of Cancer: Innovative Approaches Local Immunotherapy of Cancer: Innovative Approaches
Review the latest early research on intratumoral and intranodal immunotherapies.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer
(American Society for Radiation Oncology) Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2018 Category: International Medicine & Public Health Source Type: news

Scottish Immunotherapy Company Opens First Overseas Office in Japan
Located at the Kanagawa Prefecture (Greater Tokyo area), TC BioPharm will use the new office as a foundation to expand its cell therapy business through Japan and Asia.(PRWeb February 13, 2018)Read the full story at http://www.prweb.com/releases/2018/02/prweb15194962.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 13, 2018 Category: Pharmaceuticals Source Type: news

Researchers develop novel immunotherapy to target colorectal cancer
A Yale-led research team has developed an antibody that blocks tumors in animal models of colorectal cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 12, 2018 Category: Universities & Medical Training Source Type: news

ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
HOUSTON, Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- ImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies, today announced the appointment... Biopharmaceuticals, Oncology, Personnel ImmunoMet Therapeutics, immunotherapy, immunotherapies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2018 Category: Pharmaceuticals Source Type: news

Prostate Cancer Immunotherapy Prostate Cancer Immunotherapy
Find out more about the current landscape for prostate cancer immunotherapy and learn about potential treatment strategies.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Cancer drug development award given to Jean-Charles Soria
(European Society for Medical Oncology) The TAT 2018 Honorary Award for cancer drug development has been granted to Professor Jean-Charles Soria, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy. The award will be presented during the International Congress on Targeted Anticancer Therapies (TAT) 2018, to be held in Paris, France, March 5-7. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 12, 2018 Category: International Medicine & Public Health Source Type: news

Smart bomb virus shows promise as brain tumor immunotherapy
(University of Texas M. D. Anderson Cancer Center) A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2018 Category: Cancer & Oncology Source Type: news

Cancer killing clue could lead to safer and more powerful immunotherapies
(Walter and Eliza Hall Institute) The study, led by Dr Misty Jenkins from the Walter and Eliza Hall Institute of Medical Research, explains the crucial mechanisms by which CAR-T cell therapy is able to rapidly target and kill cancer cells, and why it may cause serious side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2018 Category: Cancer & Oncology Source Type: news

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer
(Georgetown University Medical Center) Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2018 Category: Cancer & Oncology Source Type: news

Next Steps for Immunotherapies, Cell Therapies in Oncology Next Steps for Immunotherapies, Cell Therapies in Oncology
At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Depth of Response in NSCLC with Targeted or Immunotherapies Depth of Response in NSCLC with Targeted or Immunotherapies
Greater depth of response may be associated with overall survival and progression-free survival and could be considered as an additional outcome measure for clinical trials.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Molecular 'magnets' could improve cancer immunotherapy
(The Francis Crick Institute) Chemicals that attract specialised immune cells toward tumours could be used to develop better immunotherapies for cancer patients, according to new research published in Cell.Scientists at the Francis Crick Institute have discovered that immune cells called Natural Killer cells accumulate in tumours and release chemicals that attract specialised dendritic cells (cDC1) - white blood cells known for triggering anti-cancer immune responses - to the tumour. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 8, 2018 Category: Cancer & Oncology Source Type: news

Study: Early Identification Needed for Mesothelioma Advances
Professor John Cherrie at Heriot-Watt University in the United Kingdom believes future treatment advances and improved patient outcomes for mesothelioma rests with a formula to better identify and screen high-risk patients. It could make an early diagnosis of the asbestos-related cancer much more common. Cherrie said the current standard — which typically results in a late-stage diagnosis and a poor prognosis — prevents novel treatment studies and the development of any pre-emergent strategy to combat the aggressive cancer. “We don’t pretend to have a medical cure that will help immediately, but un...
Source: Asbestos and Mesothelioma News - February 6, 2018 Category: Environmental Health Authors: Matt Mauney Tags: Activity emission potential biomarkers for mesothelioma chemoprophylaxis strategies early diagnosis mesothelioma Early identification of mesothelioma early screening asbestos Heriot-Watt University high-risk mesothelioma indwelling pleural Source Type: news

Bladder Cancer: Model Predicts Survival After Immunotherapy Bladder Cancer: Model Predicts Survival After Immunotherapy
A prognostic model based on six readily available clinical factors can help predict overall survival in patients with advanced bladder cancer receiving immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche notches fresh win amid crowd of immunotherapy cocktails
ZURICH (Reuters) - Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Movement Disorders With Neuronal Antibodies Movement Disorders With Neuronal Antibodies
This review describes the wide variety of autoantibody-related movement disorders, their pathophysiology, and current therapeutic options. Might they be targets for antigen-specific immunotherapies?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer Support for Upfront Immunotherapy in Advanced Renal Cell Cancer
Atezolizumab plus bevacizumab improves progression-free survival with greater tolerability than standard sunitinib in advanced kidney cancer in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

BMS gets boost from immunotherapy cancer trial
US drugmaker hails breakthrough as it reports rising revenues but suffers US tax hit (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 5, 2018 Category: Pharmaceuticals Source Type: news

Winship Cancer Institute names director of new Center for Cancer Immunology
Emory University's Winship Cancer Institute named Madhav V. Dhodapkhar director of its new Center for Cancer Immunology Dhodapkhar is an expert in cancer immunology and translational immunotherapy. He joins Winship from Yale University School of Medicine, where he served as chief of hematology, the Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and professor of immunobiology for the past decade. He was also co-director of the Cancer Immunology Program at the Yale Cancer Center.  The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 5, 2018 Category: Pharmaceuticals Authors: Ellie Hensley Source Type: news

Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
With the Stanford Cancer Institute joining as a clinical trial partner, Tessa's Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S. The therapy is based on Tessa's Virus-Specific T cell ... Biopharmaceuticals, Oncology Tessa Therapeutics, nasopharyngeal cancer, T cell immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2018 Category: Pharmaceuticals Source Type: news

How Cancer Immunotherapy Is Getting Even Better
Last year, the Food and Drug Administration approved two new immunotherapies to treat certain leukemias and lymphomas. Now, in a study published in the New England Journal of Medicine, researchers detail who is most likely to benefit from the treatments, called CAR T cell therapy. CAR T cell therapy trains the body’s immune system to target and destroy cancer cells in the blood; scientists take people’s own immune cells (T cells) and genetically engineer them to seek out and destroy cancer cells. The immune system can then attack cancer cells in the same way it does bacteria and viruses, and the therapy can lea...
Source: TIME: Health - February 2, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer cancer cells cancer immunotherapy CAR T car t cell therapy car t gene therapy car t therapy cure for cancer healthytime leukemia leukemia treatments Source Type: news

Build It And They Will Come
In the award-winning 1989 movie,Field of Dreams, Kevin Costner hears a voice telling him to build a baseball field on his farm in Iowa. " If you build it, he will come, ” says the voice. Against the warnings of many, and with nothing but faith, he builds the field and (spoiler alert!) his dream comes true when he meets and plays ball with his hero, baseball legend Shoeless Joe Jackson.While the pharmaceutical industry is not well-known for such whimsical notions, for a sector rooted in science, it takes a lot on faith. We – the thousands whose jobs depend on it and the millions of patients worldwide &ndash...
Source: EyeForPharma - February 2, 2018 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

Bacteria play critical role in driving colon cancers
(Johns Hopkins Medicine) Patients with an inherited form of colon cancer harbor two bacterial species that collaborate to encourage development of the disease, and the same species have been found in people who develop a sporadic form of colon cancer, a study led by a Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy research team finds. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2018 Category: International Medicine & Public Health Source Type: news

Enhancing responses to cancer immunotherapy
(Source: ScienceNOW)
Source: ScienceNOW - February 1, 2018 Category: Science Authors: Kvistborg, P., Yewdell, J. W. Tags: Immunology perspective Source Type: news

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to which patient-specific HLA-I genotype influences response to anti–programmed cell death protein 1 or anti–cytotoxic T lymphocyte–associated protein 4 is currently unknown. We determined the HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint blockade (ICB). Maximal heterozygosity at HLA-I loci ("A," "B," and "C") improved overall survival after ICB compared with patients wh...
Source: ScienceNOW - February 1, 2018 Category: Science Authors: Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., Greenbaum, B., Carroll, J., Garon, E., Hyman, D. M., Zehir, A., Solit, D., Berger, M., Zhou, R., Rizvi, N. A., Chan, T Tags: Genetics, Immunology, Medicine, Diseases reports Source Type: news

SU2C awards $11M in grants to investigate immunotherapies using AI with Microsoft support
(Entertainment Industry Foundation) SU2C awards $11M in 'Convergence 2.0' grants to investigate immune system response to cancers using Microsoft Research's machine learning and artificial intelligence. Each team comprising life sciences, physical sciences, mathematics and engineering experts will collaborate with Microsoft's machine learning experts exploring cancer/immune system interaction that can lead to development of new treatments. In addition the Lustgarten Foundation committed $1.76M; and the Society for Immunotherapy of Cancer is providing $1M to support post-doctoral fellows. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2018 Category: Cancer & Oncology Source Type: news

Moffitt researchers discover new approach to stimulate an immune response against tumor cells
(H. Lee Moffitt Cancer Center& Research Institute) A team of Moffitt Cancer Center researchers is trying to find new ways to further enhance the activity of the immune system against cancer. In an article published in the January issue of Cancer Cell, the researchers describe how a new type of immunotherapy drug targeting the protein TIM-3 works to stimulate the immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 30, 2018 Category: Cancer & Oncology Source Type: news

Immunotherapy pioneer James Allison wins the Frontiers of Knowledge Award in Biomedicine
(BBVA Foundation) The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes, in this tenth edition, to American immunologist James P. Allison, whose research, says the jury, 'had led to harnessing the immune system to combat cancer in patients and the development of new therapies.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2018 Category: International Medicine & Public Health Source Type: news

SU2C awards $11 million in grants to investigate immunotherapies using AI with Microsoft support
(Entertainment Industry Foundation) SU2C awards $11 million in 'Convergence 2.0' grants to investigate immune system response to cancers using Microsoft Research's machine learning and artificial intelligence. Each team comprising life sciences, physical sciences, mathematics and engineering experts will collaborate with Microsoft's machine learning experts exploring cancer/immune system interaction that can lead to development of new treatments. In addition the Lustgarten Foundation committed $1.76 million; and the Society for Immunotherapy of Cancer is providing $1 million to support post-doctoral fellows. (Source: Eurek...
Source: EurekAlert! - Medicine and Health - January 30, 2018 Category: International Medicine & Public Health Source Type: news

Cancer Immunotherapy May Be Safe for Rheumatology Patients Cancer Immunotherapy May Be Safe for Rheumatology Patients
A minority of those who received immune checkpoint inhibitors and had underlying rheumatologic disease experienced flare-ups or adverse effects, a small study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 29, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New Genetic Sequence Data Map May Lead to New Immunotherapies
ImmunoMap, which can examine T-cell receptor repertoire relatedness, may help predict clinical outcome for patients with cancer and could be a new tool for designing vaccines and immunotherapies. (Source: CancerNetwork)
Source: CancerNetwork - January 26, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Cancer and Genetics News Source Type: news

Second Bay Area biotech IPO this week soars after topping targets, raising $128 million
Shares of ARMO Biosciences Inc. jumped by as much as 83 percent after the Redwood City biotech raised $128 million in the second successful Bay Area IPO this week. The Redwood City-based cancer immunotherapy developer sold 7.5 million shares at $17 each. It originally planned to sell 6.7 million shares for between $14 and $16.  The offering follows one from Menlo Therapeutics Inc. (NASDAQ:MNLO) the day before, during which its stock soared 69 percent above its IPO price after raising $119 million.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 26, 2018 Category: Pharmaceuticals Authors: Cromwell Schubarth Source Type: news

Second Bay Area biotech IPO this week soars after topping targets, raising $128M
Shares of ARMO Biosciences Inc. jumped by as much as 83 percent after the Redwood City biotech raised $128 million in the second successful Bay Area IPO this week. The Redwood City-based cancer immunotherapy developer sold 7.5 million shares at $17 each. It originally planned to sell 6.7 million shares for between $14 and $16.  The offering follows one from Menlo Therapeutics Inc. (NASDAQ:MNLO) a day before in which its stock soared 69 percent above its IP O price after raising $119 million. ARMO's… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 26, 2018 Category: Pharmaceuticals Authors: Cromwell Schubarth Source Type: news

Gene therapy using CAR T cells could provide long-term protection against HIV
FINDINGSA UCLA-led research team has created blood-forming stem cells that can carry a gene that allows the body to produce cells that can detect and destroy HIV-infected cells. The blood-forming cells, called hematopoietic stem and progenitor cells, or HSPCs, have been engineered to carry chimeric antigen receptor, or CAR, genes that allows the production of immune cells that target cells infected with HIV.After being transplanted into the body, the engineered cells formed immune cells that not only destroyed the infected cells, but also lived for more than two years. This suggests that they have the potential to give peo...
Source: UCLA Newsroom: Health Sciences - January 25, 2018 Category: Universities & Medical Training Source Type: news